What Gilead Sciences (GILD) Said on Its Q3 Earnings Call

Gilead Sciences (GILD) raised its 2026 sales forecast to $30.7B-$31B, citing strong HIV sales growth and new product launches. TRODELVY sales rose 42% YoY to $506M, while Livdelzi sales increased 93% YoY to $203M. Cell therapy sales declined 18% YoY. The company expects BIKTARVY revenue to be impacted by Medicare pricing but anticipates overall HIV revenue growth in 2028.

Original reporting
Published Oct 30, 2026, 12:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 12:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What Gilead Sciences (GILD) Said on Its Q3 Earnings Call — source image
Decision brief

The 30-second read

$GILDNeutralMed
01

Why it matters

Traders can update models using the raised 2026 sales forecast and the quantified Medicare-driven net impact on Biktarvy revenue in 2028, while also tracking oncology and cell-therapy catalysts mentioned on the call.

02

Market read

The article provides concrete forward guidance and a quantified payer-channel revenue impact for Gilead’s core HIV franchise, which can drive near-term positioning and longer-dated valuation adjustments.

03

What to watch

Inventory building guidance (smaller Q4 build) and the timing of anito-cel FDA decision (Dec. 23) could dominate near-term sentiment versus the longer-dated 2028 Biktarvy impact.

Relevance 8/10Novelty 7/10Timing: post-market, immediately actionable for positioning ahead of follow-through on guidance and payer-price updates

Background

The piece summarizes Gilead’s Q3 earnings call, including new HIV product launch details, updated financial guidance, and payer pricing updates for Biktarvy.

Company-level read

Ticker impact

$GILDNeutralHigh confidence
Context

Gilead raised 2026 base business sales guidance and quantified a Medicare-driven net $1.5B 2028 Biktarvy revenue impact on its Q3 call.

Expected impact

Likely choppy trading as investors weigh higher 2026 outlook against the disclosed multi-year Biktarvy revenue drag from Medicare pricing.

Evidence & confidence

The article includes specific forward guidance ranges and a quantified payer-channel impact tied to Biktarvy, which directly informs valuation and segment mix.

Market effects

Biopharma HIV and payer-pricing narratives may reprice as Medicare maximum fair price mechanics are quantified for a major franchise.

US-focused payer channel details (Medicare, Medicaid, 340B) can influence sentiment toward US commercial and government reimbursement dynamics.

European approvals and pipeline timelines can support broader investor risk appetite for HIV oncology cross-platform franchises, but the quantified impact is US-centric.

Counterpoint

The disclosed Biktarvy Medicare drag is netted and framed within a broader expectation of total HIV revenue growth, so the market may overreact to the headline pressure.

Key entities

  • Gilead Sciences

    Raised 2026 base business sales forecast and disclosed a quantified Medicare-driven net impact on Biktarvy revenue in 2028.

  • Biktarvy

    Medicare maximum fair price set at $2,600 per 30-day supply; company expects about $1.5B net revenue impact in 2028.

  • TRODELVY

    Sales growth and a European approval update for TRODELVY plus pembrolizumab in first-line PD-L1-positive metastatic triple-negative breast cancer.

  • Livdelzi

    Sales growth and plans for global filings to add Phase III IDEAL data, with potential US label update in 2027.

  • anito-cel

    Gilead/Kite preparing for a Dec. 23 FDA decision for fourth-line or later relapsed or refractory multiple myeloma.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$PFEMedAI 8/10

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout

Pfizer and Blackstone Life Sciences agreed to co-fund berobenatide, a GLP-1 drug for weight management, with Blackstone covering up to $1.5B in development costs. Pfizer retains control. J&J acquired Ollin Biosciences for $2.2B, Lilly acquired Calytrix Bio for up to $1.5B, and Sanofi partnered with Seawolf Therapeutics. Gilead licensed obeldesivir to generic manufacturers for Ebola prevention. The FDA approved Novartis' Cosentyx for polymyalgia rheumatica and Roche's Wilserdly for breast cancer.

$GSKMed

The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs

The Liver Meeting 2026 highlighted advancements in hepatitis delta, PBC, and MASH treatments. Vir Biotechnology's elebsiran and Mirum Pharmaceuticals' brelovitug showed promising phase 3 results for hepatitis delta, with regulatory submissions expected in 2027. GSK's bepirovirsen received FDA approval for hepatitis B. Merck's efinopegdutide and Altimmune's pemvidutide showed potential in MASH treatment. Real-world data indicated cost concerns with MASH therapies.

$GILDMed

Phase 3 Data Back ALP Normalization as Treatment Goal in PBC

Phase 3 trials show elafibranor (Ipsen) and seladelpar (Gilead Sciences) effectively normalize ALP levels in PBC patients. Both drugs were approved in 2024 for inadequate UDCA response. Trials reported significant ALP reduction and normalization rates, with safety profiles similar to placebo.

$GILDMed

Invikafusp Alfa Plus Sacituzumab Govitecan Generates Responses in Metastatic TNBC and HR+/HER2– Breast Cancer

A phase 1b/2 trial showed a 28% ORR in TNBC and 25% in HR+/HER2– breast cancer patients treated with invikafusp alfa and sacituzumab govitecan. The combination demonstrated preliminary antitumor activity with no new safety signals. Sacituzumab govitecan is FDA-approved for these indications. The trial's lead author noted the potential for deeper immune responses in historically resistant tumors.